Fulgent Genetics Reports First Quarter 2018 Financial Results

Genetics Investing

Fulgent Genetics (NASDAQ:FLGT) announced financial results for its first quarter ended March 31, 2018. As quoted in the press release: First quarter revenue was $4.7 million, an increase of 9% sequentially from $4.3 million in the fourth quarter of 2017, and a decrease of 12% year over year from $5.3 million in the first quarter …

Fulgent Genetics (NASDAQ:FLGT) announced financial results for its first quarter ended March 31, 2018.

As quoted in the press release:

First quarter revenue was $4.7 million, an increase of 9% sequentially from $4.3 million in the fourth quarter of 2017, and a decrease of 12% year over year from $5.3 million in the first quarter of 2017. GAAP loss for the first quarter of 2018 was $1.9 million, or $0.11 per share, and non-GAAP loss was $1.2 million, or $0.06 per share. Adjusted EBITDA loss was $1.1 million in the first quarter of 2018.
Non-GAAP loss and adjusted EBITDA are described below under “Note Regarding Non-GAAP Financial Measures” and are reconciled to the most directly comparable GAAP financial measure, GAAP income (loss), in the accompanying tables.

Click here to read the full press release.